Skip to content

Inspection Record

WuXi Biologics Ireland Limited — FDA 483 Findings

US FDAInspected 2025-12-16Published 2026-10-22 3 findingsEquipment and facilityLaboratory and QC controlsDeviation, CAPA, and investigation

View the regulator's official source The source document is always the basis for judgement.

Findings

1Equipment and facility

(4) equipment utilized in the mw drug substance manufacturing process is deficient.

2Laboratory and QC controls

Laboratory controls are inadequate to ensure reliable analytical testing of critical quality and safety attributes.

A record as of the US FDA document published on 2026-10-22. Check the agency's announcements for any later corrective action, and rely on the original text. Translation and classification are machine-made.

WuXi Biologics Ireland Limited company profile — full historyAll US FDA findings US FDA documents, 2026 Go to Findings search
Linked from (backlinks)
Briefs that featured this document
Weekly Newsletter

Get new findings like these every Monday

Every Monday we email the week's new findings and actions from the FDA, EMA, Health Canada and MFDS. Each one links to its record on our site, where you'll find the regulator's original document. We'll also let you know when the site gains new features. Unsubscribe any time with one click.

See recent findings first

Sent every Monday · a confirmation email follows when you subscribe · unsubscribe from the footer of any email.